Valuation: Zai Lab Limited

Market Cap 2.02B 1.77B 1.63B 1.53B 2.87B 191B 2.93B 19.65B 7.6B 94.29B 7.59B 7.43B 327B P/E 2026 *
-8.13x
P/E 2027 * -9.65x
Enterprise Value 1.58B 1.38B 1.28B 1.19B 2.24B 149B 2.29B 15.34B 5.94B 73.63B 5.93B 5.8B 255B EV / Sales 2026 *
3.52x
EV / Sales 2027 * 2.75x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 60 01/04/2014
Director/Board Member 82 01/01/2017
Director/Board Member 74 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 2.02B
+2.06%+3.76%+21.48%-11.62% 64.39B
+0.74%+3.52%+51.88%+225.16% 56.12B
-3.10%+34.30%+34.30%+34.30% 40.54B
-2.36%-1.25%-50.98%-58.84% 37.98B
+6.97%+9.89%+71.34%-23.65% 31.89B
+12.59%+5.18%+147.68%-44.25% 26.69B
+5.78%+15.81%+66.37%+84.42% 22.73B
-1.25%-1.31%-2.84%+151.34% 16.66B
-0.81%+5.91%+63.81%+125.65% 16.6B
Average +2.06%+4.32%+44.78%+53.61% 34.84B
Weighted average by Cap. +1.95%+4.11%+39.81%+49.85%

Financials

2026 *2027 *
Net sales 449M 393M 363M 340M 637M 42.33B 650M 4.36B 1.69B 20.92B 1.68B 1.65B 72.54B 596M 522M 481M 451M 845M 56.18B 863M 5.79B 2.24B 27.77B 2.24B 2.19B 96.28B
Net income -241M -211M -195M -182M -342M -22.72B -349M -2.34B -905M -11.23B -905M -885M -38.94B -156M -137M -126M -118M -222M -14.76B -227M -1.52B -588M -7.29B -588M -575M -25.3B
Net Debt -443M -389M -358M -335M -629M -41.8B -642M -4.3B -1.67B -20.66B -1.66B -1.63B -71.64B -387M -339M -313M -293M -549M -36.52B -561M -3.76B -1.46B -18.05B -1.45B -1.42B -62.59B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Trader
Investor
-
Global
-
Quality
ESG MSCI
A